Elucidating the mechanistic pathways of ischaemic preconditioning and postconditioning in the clinical setting

ISRCTN ISRCTN49989273
DOI https://doi.org/10.1186/ISRCTN49989273
Protocol serial number 4058
Sponsor University College London (UCL) (UK)
Funder British Heart Foundation (BHF) (UK)
Submission date
18/06/2010
Registration date
18/06/2010
Last edited
07/03/2014
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Derek Yellon
Scientific

The Hatter Institute for Cardiovascular Studies
25 Grafton Way
London
WC1E 6DB
United Kingdom

Email d.yellon@ucl.ac.uk

Study information

Primary study designInterventional
Study designMulticentre randomised interventional treatment trial
Secondary study designRandomised controlled trial
Study type Participant information sheet
Scientific titleA multicentre randomised interventional treatment trial to explore the mechanistic pathway of ischaemic preconditioning and postconditioning in the clinical settings of myocardial ischaemia-reperfusion injury
Study acronymACE - CABG/PPCI
Study objectivesThe aim of the study is use pharmacological agents that have been shown to activate survival kinases and inhibit mPTP opening to explore the mechanistic pathway of ischaemic preconditioning and postconditioning in the clinical settings of myocardial ischaemia-reperfusion injury. Patients who are due to undergo planned cardiac surgery will be recuited to receive an interventional agent. These patients will be randomised and compared against a group of controls. Blood tests would be taken post-operatively to assess the primary end points.
Ethics approval(s)The Joint UCL/UCLH Committees on the Ethics of Human Research Committee (Alpha) approved on the 23/11/2006 (ref: 06/Q0502/83)
Health condition(s) or problem(s) studiedTopic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular
Intervention1. Intervention 1: Cyclosporin A at dose of 2.5 mg/kg; diluted in 100 ml of normal saline. Once only dose given over 30 minutes prior to surgery.
2. Intervention 2: Atorvastatin at a dose of 160 mg; given on the morning of surgery and a second dose of 160 mg repeated 24 hours later
3. Intervention 3: Erythropoietin at a dose of 50,000 IU; given as an infusion of 50 ml over 30 minutes prior to revascularisation. A second dose is repeated 24 hours later.
Intervention typeOther
Primary outcome measure(s)

Serum cTnT and CK-MB (bloods taken before intervention and at 6, 12, 24, 48 and 72 hours post-intervention).

Key secondary outcome measure(s)

1. Inotropic score: calculated using the maximum inotropic dose used on day 1 post-op
2. Ventilation time: assessed from the time of admission into ITU to the time of extubation
3. ITU stay: assessed from the time of admission into ITU to the time of discharge from the unit

Completion date30/06/2010

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexAll
Target sample size at registration400
Key inclusion criteriaPatients experiencing an event or procedure which will bring about myocardial injury:
1. Coronary artery bypass surgery +/- valve surgery
2. Primary angioplasty for ST elevation myocardial infarction
3. Thrombolysis for ST elevation myocardial infarction
4. Non-ST elevation myocardial infarction
5. High risk and undergoing percutaneous coronary intervention
6. Aged 18 - 85 years, either sex
Key exclusion criteria1. Significant co-morbidity
2. Known intolerance to trialled intervention
3. Renal/liver failure
4. In patients undergoing an elective procedure-chest pain within the last 3 days, lack of consent
Date of first enrolment01/06/2007
Date of final enrolment30/06/2010

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

The Hatter Institute for Cardiovascular Studies
London
WC1E 6DB
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/04/2014 Yes No
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes